Wells Fargo & Company Aerovate Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVTE
# of Institutions
81Shares Held
20.3MCall Options Held
0Put Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$6.05 Million6.47% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.2MShares$3.54 Million6.85% of portfolio
-
Atlas Venture Life Science Advisors, LLC2.04MShares$3.28 Million7.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.68MShares$2.71 Million0.63% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.2MShares$1.94 Million1.87% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $39.4M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...